Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease

Tomonori Kimura, Kenji Hamase, Yurika Miyoshi, Ryohei Yamamoto, Keiko Yasuda, Masashi Mita, Hiromi Rakugi, Terumasa Hayashi, Yoshitaka Isaka

Research output: Contribution to journalArticlepeer-review

140 Citations (Scopus)


D-Amino acids, the enantiomers of L-amino acids, are increasingly recognized as novel biomarkers. Although the amounts of D-amino acids are usually very trace in human, some of them have sporadically been detected in blood from patients with kidney diseases. This study examined whether multiple chiral amino acids would be associated with kidney functions, comorbidities, and prognosis of chronic kidney disease (CKD) by enantioselective analyses of all chiral amino acids with a micro-two-dimensional high-performance liquid chromatograph (2D-HPLC)-based analytical platform. 16 out of 21 D-amino acids were detected in plasma from 108 CKD patients in a longitudinal cohort. The levels of D-Ser, D-Pro, and D-Asn were strongly associated with kidney function (estimated glomerular filtration ratio), the levels of D-Ala and D-Pro were associated with age, and the level of D-Asp and D-Pro were associated with the presence of diabetes mellitus. D-Ser and D-Asn were significantly associated with the progression of CKD in mutually-adjusted Cox regression analyses; the risk of composite end point (developing to ESKD or death before ESKD) was elevated from 2.7- to 3.8-fold in those with higher levels of plasma D-Ser and D-Asn. These findings identified chiral amino acids as potential biomarkers in kidney diseases.

Original languageEnglish
Article number26137
JournalScientific reports
Publication statusPublished - May 18 2016

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease'. Together they form a unique fingerprint.

Cite this